Cooper Companies Inc (NYSE:COO) – Stock analysts at KeyCorp issued their Q1 2019 earnings estimates for Cooper Companies in a report released on Wednesday, December 5th. KeyCorp analyst M. Mishan forecasts that the medical device company will earn $2.69 per share for the quarter. KeyCorp has a “Overweight” rating and a $296.00 price objective on the stock. KeyCorp also issued estimates for Cooper Companies’ Q2 2019 earnings at $2.97 EPS, Q3 2019 earnings at $3.17 EPS, Q4 2019 earnings at $3.23 EPS, FY2019 earnings at $12.05 EPS and FY2020 earnings at $13.89 EPS.

Cooper Companies (NYSE:COO) last posted its earnings results on Thursday, December 6th. The medical device company reported $2.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.96 by ($0.09). Cooper Companies had a net margin of 5.23% and a return on equity of 17.53%. The firm had revenue of $651.50 million during the quarter, compared to analyst estimates of $645.25 million. During the same quarter in the prior year, the firm earned $2.65 earnings per share. The business’s revenue for the quarter was up 16.0% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on the stock. BMO Capital Markets upped their price objective on shares of Cooper Companies from $280.00 to $285.00 and gave the stock an “outperform” rating in a research report on Friday, August 31st. Oppenheimer set a $270.00 price objective on shares of Cooper Companies and gave the stock a “hold” rating in a research report on Friday, August 31st. Raymond James upped their price objective on shares of Cooper Companies from $270.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, September 21st. Zacks Investment Research cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Finally, Wells Fargo & Co upped their price objective on shares of Cooper Companies from $295.00 to $305.00 and gave the stock an “outperform” rating in a research report on Friday. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $284.50.

COO opened at $243.01 on Friday. The company has a quick ratio of 1.54, a current ratio of 2.58 and a debt-to-equity ratio of 0.70. Cooper Companies has a 1 year low of $216.47 and a 1 year high of $283.18. The firm has a market capitalization of $13.51 billion, a P/E ratio of 25.05, a PEG ratio of 2.11 and a beta of 0.77.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bradley Foster & Sargent Inc. CT raised its position in shares of Cooper Companies by 10.1% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 2,184 shares of the medical device company’s stock valued at $605,000 after buying an additional 200 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Cooper Companies by 16.5% in the third quarter. Penserra Capital Management LLC now owns 1,564 shares of the medical device company’s stock valued at $433,000 after buying an additional 221 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of Cooper Companies by 21.9% in the third quarter. Mackenzie Financial Corp now owns 1,237 shares of the medical device company’s stock valued at $343,000 after buying an additional 222 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in shares of Cooper Companies by 6.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,622 shares of the medical device company’s stock valued at $853,000 after buying an additional 232 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its position in shares of Cooper Companies by 1.3% in the second quarter. Nomura Asset Management Co. Ltd. now owns 19,770 shares of the medical device company’s stock valued at $4,655,000 after buying an additional 262 shares during the last quarter.

In other Cooper Companies news, VP Randal Golden sold 1,731 shares of the company’s stock in a transaction on Thursday, September 27th. The shares were sold at an average price of $275.86, for a total transaction of $477,513.66. Following the completion of the transaction, the vice president now directly owns 1,154 shares in the company, valued at $318,342.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Allan E. Rubenstein sold 1,500 shares of the company’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $265.37, for a total transaction of $398,055.00. Following the transaction, the director now owns 3,068 shares of the company’s stock, valued at $814,155.16. The disclosure for this sale can be found here. Insiders have sold 20,691 shares of company stock valued at $5,527,869 over the last 90 days. 1.60% of the stock is currently owned by company insiders.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Article: How analysts view the yield curve

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.